A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Medications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

A diabetes medication that lowers brain fluid pressure has ... Headache Centre of the University of Naples “Federico II” gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Wegovy will be available in India in five strengths. While the lower doses (0.25 mg, 0.5 mg, and 1 mg) will be priced at ...